Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Nipped-B homolog pseudogene" (ENSG00000253233) is a DNA segment in the human genome resembling the Nipped-B homolog (NIPBL) gene but lacking the ability to produce a functional protein. Pseudogenes like this are formed through gene duplication or retrotransposition events, resulting in a sequence similar to the original gene but usually lacking regulatory elements and/or being disrupted by mutations such as premature stop codons or frameshifts[1][3]. As a pseudogene, ENSG00000253233 is not considered a therapeutic target and has no known direct biological function, disease association, or interactions with drugs[5][1]. Confusion can arise because the protein-coding NIPBL gene is an important target in human genetics, whereas its pseudogene variant is not functionally active[5][2][6]. This molecule serves primarily as a genomic reference and should not be used as a target in structured therapeutic or mechanistic databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nipped-B homolog pseudogene.